A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL Post author: Post published:March 1, 2026 Post category: Continue ReadingBAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 Post author: Post published:March 1, 2026 Post category: Continue ReadingA Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia Post author: Post published:March 1, 2026 Post category: Continue ReadingA Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Post author: Post published:March 1, 2026 Post category: Continue ReadingLong-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs Post author: Post published:March 1, 2026 Post category: Continue ReadingLeading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
